NCT02667574 (VISMONEO) is a Phase 2 clinical trial of ERIVEDGE in Basal Cell Carcinoma, sponsored by University Hospital, Lille.

Who is sponsoring NCT02667574?

NCT02667574 is sponsored by University Hospital, Lille.

What drugs are being tested in NCT02667574?

Interventions in NCT02667574: ERIVEDGE.

What condition does NCT02667574 study?

NCT02667574 studies Basal Cell Carcinoma.

Is NCT02667574 still recruiting?

NCT02667574 is currently completed. Last updated 17 October 2022.

Last reviewed 2022-10-17 · How we verify

NCT02667574: VISMONEO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC)

Completed Phase 2 Last updated 17 October 2022

What this trial tests

Phase 2 trial testing ERIVEDGE in Basal Cell Carcinoma in 55 participants. Completed in 15 July 2020.

Timeline

18 November 2014

Primary endpoint
15 July 2020

15 July 2020

Quick facts

Lead sponsor	University Hospital, Lille
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	55
Start date	18 November 2014
Primary completion	15 July 2020
Estimated completion	15 July 2020
Sites	17 locations across France

Drugs / interventions tested

ERIVEDGE (vismodegib) — full drug profile →

Conditions studied

Basal Cell Carcinoma — all drugs for Basal Cell Carcinoma →

Sponsor

University Hospital, Lille

Who can join

18 and older, any sex, with Basal Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Open-label, non-comparative, multicenter, phase II study of Vismodegib in patients with locally advanced BCC.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Hedgehog Signaling in Cancer: A Prospective Therapeutic Target for Eradicating Cancer Stem Cells.
Sari IN, Phi LTH, Jun N, Wijaya YT, et al · · 2018 · cited 155× · PMID 30423843 · DOI 10.3390/cells7110208
Characteristics of the cancer stem cell niche and therapeutic strategies.
Ju F, Atyah MM, Horstmann N, Gul S, et al · · 2022 · cited 84× · PMID 35659296 · DOI 10.1186/s13287-022-02904-1
Update in the Management of Basal Cell Carcinoma.
Basset-Seguin N, Herms F. · · 2020 · cited 83× · PMID 32346750 · DOI 10.2340/00015555-3495
Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study): Neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma.
Bertrand N, Guerreschi P, Basset-Seguin N, Saiag P, et al · · 2021 · cited 69× · PMID 33997740 · DOI 10.1016/j.eclinm.2021.100844
Cancer-associated fibroblasts as therapeutic targets for cancer: advances, challenges, and future prospects.
Cao Z, Quazi S, Arora S, Osellame LD, et al · · 2025 · cited 57× · PMID 39780187 · DOI 10.1186/s12929-024-01099-2
Signaling pathways in the regulation of cancer stem cells and associated targeted therapy.
Manni W, Min W. · · 2022 · cited 52× · PMID 36226253 · DOI 10.1002/mco2.176
The role of Hedgehog and Notch signaling pathway in cancer.
Xia R, Xu M, Yang J, Ma X. · · 2022 · cited 39× · PMID 36517618 · DOI 10.1186/s43556-022-00099-8
Known and new facts on basal cell carcinoma.
Seidl-Philipp M, Frischhut N, Höllweger N, Schmuth M, et al · · 2021 · cited 31× · PMID 34288482 · DOI 10.1111/ddg.14580

Verify or expand the search:

Other recruiting trials for Basal Cell Carcinoma

Currently open trials in the same condition.

NCT07182240 — Pilot Study of Line-Field Confocal Optical Coherence Tomography for Detection of Mohs Micrographic Surgery Margins of Ba · NA · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT06600165 — Intraoperative Confocal Laser Scanning Microscopy With Use of AI for Optimized Surgical Excision of Basal Cell Carcinoma · recruiting
NCT06384924 — Raman Spectroscopy and Skin Cancer · recruiting
NCT06384053 — Skin Cancer and Hyperthermia and Radiotherapy · NA · recruiting

Other University Hospital, Lille trials

Trials by the same sponsor.

NCT07528664 — Assessement of a Test a Financial-incentive Program for Pregnant Women and Their Smoking Partners to Reduce Smoking Duri · NA · not yet recruiting
NCT07434739 — PAravertebral CaTheter Versus Epidural Analgesia in Totally Minimally Invasive Esophagectomies · NA · not yet recruiting
NCT06958224 — Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers · NA · not yet recruiting
NCT07408999 — Totally Versus Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer · NA · not yet recruiting
NCT07492030 — Validation of the Use of the Arteriovenous Tension Difference in CO2 Under Hyperbaric Conditions · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02667574 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Lille
Last refreshed: 17 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02667574.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing